"This study helps to define a novel resistance pathway for abiraterone, a commonly used medication for patients with advanced prostate cancer", commented Howard Soule, PhD, executive vice president and chief science officer, nonprofit Prostate Cancer Foundation - which supported the study in part with grant money.
The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic prostate cancer.
"In addition, the risk of dying from prostate cancer for African-American men is about 4 percent compared to about 2 percent for white men".
Those who ate dinner earlier and more closely adhered to a healthy lifestyle had a 35 percent decrease change of developing prostate and breast cancer.
Trump's invitation to Putin draws rebukes from Democrats and his intelligence chief
Mr Putin said Russian Federation wanted to question United States nationals the Kremlin accuses of "illegal actions". Trump had said he and Putin discussed reducing nuclear weapons worldwide.
Breast and prostate cancers are also among those most strongly associated with night-shift work, circadian disruption and adjustment of biological rhythms.
The investigators aim to enroll 10,000 African-American men with prostate cancer into the RESPOND study. According to Cancer.gov, breast cancer is the most common cancer, with the next most common cancers being lung cancer and - you guessed it, prostate cancer.
Cancer is complex and diet certainly is not the only thing that affects cancer risk. They will also study DNA and tumor samples to identify gene variants associated with aggressive prostate cancer. Probably not, but new research suggests that you might want to consider it. "The ability to integrate genetic and environmental factors, including individual, neighborhood, and societal factors, into one large study will enable us to have a better understanding of how all of these factors contribute to the aggressiveness of prostate cancer". New Jersey State Cancer Registry Director Antoinette Stroup, PhD of Rutgers Cancer Institute of New Jersey along with Karen Pawlish, PhD of the New Jersey Department of Health, are among the nationwide collaborators on the "RESPOND" study being led by the Keck School of Medicine of the University of Southern California (USC).
NCI's Division of Cancer Epidemiology and Genetics will perform genotyping, and the Center for Inherited Disease Research at Johns Hopkins University will conduct DNA sequencing for the genetic component of the study. The control group consisted of 1 321 female and 872 men with no cancer. It is expected that the information gained from RESPOND will lead to more effective interventions for preventing the disease, reducing late-stage diagnosis, and developing novel treatment strategies for African-American men.